MBA MBA - MBX Biosciences, Chief Officer
| MBX Stock | 19.83 1.14 5.44% |
Executive
MBA MBA is Chief Officer of MBX Biosciences, Common
| Age | 60 |
| Address | 11711 N. Meridian Street, Carmel, IN, United States, 46032 |
| Phone | (317) 659-0200 |
| Web | https://mbxbio.com |
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Hassman | Scpharmaceuticals | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| MD FAAP | Lumos Pharma | N/A | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| Lee Flowers | HCW Biologics | 78 | |
| John PharmD | Scpharmaceuticals | N/A | |
| David MS | Ikena Oncology | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Bob Lally | Ikena Oncology | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Caroline MD | Ikena Oncology | 52 | |
| Lisa MD | Seres Therapeutics | 65 | |
| Leesa Gentry | RenovoRx | 54 | |
| Samuel MD | Tempest Therapeutics | 58 | |
| Ryan Witt | RenovoRx | N/A | |
MBX Biosciences, Common Leadership Team
Elected by the shareholders, the MBX Biosciences,'s board of directors comprises two types of representatives: MBX Biosciences, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MBX. The board's role is to monitor MBX Biosciences,'s management team and ensure that shareholders' interests are well served. MBX Biosciences,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MBX Biosciences,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michelle Graham, Chief Officer | ||
| Peter MBA, President CEO | ||
| Salomon Azoulay, Chief Officer | ||
| MBA MBA, Chief Officer | ||
| Matt Gambino, Vice Marketing | ||
| Richard CPA, Chief Officer |
MBX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MBX Biosciences, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 613.91 M | ||||
| Shares Outstanding | 31.85 M | ||||
| Shares Owned By Insiders | 3.08 % | ||||
| Shares Owned By Institutions | 54.94 % | ||||
| Number Of Shares Shorted | 345.33 K | ||||
| EBITDA | (50.72 M) | ||||
| Total Debt | 156.65 M | ||||
| Book Value Per Share | (6.18) X | ||||
| Earnings Per Share | (1.48) X | ||||
| Number Of Employees | 38 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MBX Stock Analysis
When running MBX Biosciences,'s price analysis, check to measure MBX Biosciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MBX Biosciences, is operating at the current time. Most of MBX Biosciences,'s value examination focuses on studying past and present price action to predict the probability of MBX Biosciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MBX Biosciences,'s price. Additionally, you may evaluate how the addition of MBX Biosciences, to your portfolios can decrease your overall portfolio volatility.